Regulators in the UK will only conduct essential on-site inspections of clinical trials, distribution, laboratories, manufacturing and pharmacovigilance during the COVID-19 outbreak, according to new guidances issued last week.

The Medicines and Healthcare products Regulatory Agency (MHRA) says all other inspections will be deferred until further notice.

The guidances also recommend remote monitoring of participants and replacing in-person visits with phone calls and that on-site inspections associated with the UK government’s response to COVID-19 or other public health risks be prioritized over other trials.

To read the guidances, click here: https://bit.ly/2UJlXph and https://bit.ly/2UJWyvV.